Lactulose
Brand names: Lactulose Solution
Lactulose is an osmotic laxative, a semi-synthetic disaccharide, used to treat constipation.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is not absorbed from the gut and is fermented by colonic bacteria to organic acids, which exert an osmotic effect that increases water content and softens the stool, promoting bowel movement.
Prescribing in practice
- It should be avoided in galactosaemia and in patients with intestinal obstruction, and used with caution in lactose intolerance.
- Its laxative effect may take a couple of days to develop, so it is not suitable for rapid relief of constipation.
- Flatulence and abdominal cramps are common, particularly when starting, and tend to settle with continued use.
Monitoring
Routine monitoring is not generally required; assess the clinical response and adjust the dose to produce a comfortable, soft stool.
Counselling the patient
- The medicine may take a day or two to work, so do not increase the dose too quickly.
- Wind and mild cramping are common at first and usually settle; maintain a good fluid intake.
Evidence & guidelines
Lactulose is a long-established osmotic laxative recommended for constipation in national prescribing guidance.
Reference: NICE NG215 Cirrhosis; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021